Avvinity is deploying a powerful and proprietary platform to discover and develop novel immuno-oncology therapeutics, called Alphamers for both solid tumours and leukaemias.
The scientific partnership brings together Centauri’s Alphamer platform and extensive experience in drug discovery and immunology with Horizon’s gene editing, immunology and translational oncology capabilities.
We are a capital-efficient virtual company deploying up to £5.3million of initial funding and contracting our member companies to perform work on our behalf. We plan to develop Alphamer drug candidates against a number of targets of unmet therapeutic need and then raise additional funds to take them into clinical trials.
To view the press release announcing the partnership, see below:
© 2017 Horizon Discovery. All Rights Reserved